Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands

Sabina Kersting, Suzanne I. M. Neppelenbroek, Hein P. J. Visser, Michel van Gelder, Mark-David Levin, Rogier Mous, Ward Posthuma, Hanneke M. van der Straaten, Arnon P. Kater

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)52-57
Number of pages6
JournalClinical Lymphoma Myeloma & Leukemia
Volume18
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • Chemo-immunotherapy
  • Health economics
  • Kinase inhibitors
  • Reimbursement
  • Small lymphocytic lymphoma
  • PREVIOUSLY UNTREATED PATIENTS
  • STEM-CELL TRANSPLANTATION
  • 1ST-LINE TREATMENT
  • PLUS CHLORAMBUCIL
  • PHASE-3 TRIAL
  • OPEN-LABEL
  • RITUXIMAB
  • BENDAMUSTINE
  • IBRUTINIB
  • CYCLOPHOSPHAMIDE

Cite this

Kersting, S., Neppelenbroek, S. I. M., Visser, H. P. J., van Gelder, M., Levin, M-D., Mous, R., Posthuma, W., van der Straaten, H. M., & Kater, A. P. (2018). Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands. Clinical Lymphoma Myeloma & Leukemia, 18(1), 52-57. https://doi.org/10.1016/j.clml.2017.09.015